Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favezelimab and Pembrolizumab in Hematologic Malignancies
NCT03598608Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Oct 2018
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of favezelimab in classical Hodgkin lymphoma (cHL), diffuse large B-cell lymphoma (DLBCL), Indolent Non-Hodgkin Lymphoma (INHL), sponsored by Merck & Co.. Started Oct 2018; status: terminated.
02
Drugs
favezelimab
03
Conditions
classical Hodgkin lymphoma (cHL)diffuse large B-cell lymphoma (DLBCL)Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT03598608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03598608.